2025-11-05T07:37:39-06:00 2024-12-31 260794367 UHY ADVISORS MID-ATLANTIC INC 8601 ROBERT FULTON DRIVE SUITE 210 COLUMBIA MD 21046 990 2024-01-01 452410498 RX-360 INTERNATIONAL PHARMACEUTICAL SUPPLY CHAIN CONSORTIUM RX-3 8882181164 1617 RFK BLVD 546 PHILADELPHIA PA 19103 JAMES FRIES CEO 8882181164 2025-11-04 1 0 HSUANYI WANG P03292356 4107205220 2025-11-04 2024 2025-03-06 01:10:19Z JAMES FRIES 1617 RFK BLVD 546 PHILADELPHIA PA 19103 4971657 0 X WWW.RX-360.ORG X 2009 PA (SEE SCHEDULE O)THE ORGANIZATION'S MISSION IS TO PROTECT PATIENT SAFETY BY SHARING INFORMATION AND DEVELOPING PROCESSES RELATED TO THE INTEGRITY OF THE HEALTHCARE SUPPLY CHAIN AND THE QUALITY OF MATERIALS WITHIN THE SUPPLY CHAIN. 16 16 20 19 0 0 0 0 4193079 4896067 18760 73741 2653 1849 4214492 4971657 0 0 0 0 1521272 2129676 0 0 0 2020363 2060775 3541635 4190451 672857 781206 3660812 5825545 1146494 2627686 2514318 3197859 THE ORGANIZATION'S MISSION IS TO PROTECT PATIENT SAFETY BY SHARING INFORMATION AND DEVELOPING PROCESSES RELATED TO THE INTEGRITY OF THE HEALTHCARE SUPPLY CHAIN AND THE QUALITY OF MATERIALS WITHIN THE SUPPLY CHAIN. 0 0 2648082 4896067 ENHANCING THE SECURITY OF THE PHARMACEUTICAL SUPPLY CHAIN THROUGH TWO AUDIT PROGRAMS AND RESEARCH PROGRAMS. THE RX-360 AUDIT SHARING PROGRAM ALLOWS RX-360 TO LICENSE SUPPLIER QUALITY AUDITS CONDUCTED BY RX-360 IN A CONFIDENTIAL MANNER. THE RX-360 JOINT AUDITING PROGRAM ALLOWS RX-360 TO CONDUCT JOINT CONDUCT JOINT QUALITY AUDITS OF PHARMACEUTICAL SUPPLIES. RX-360 ALSO ANALYZES NEW LEGISLATION, REGULATIONS, STANDARDS, AND OTHER DEVELOPMENTS THAT IMPACT THE PHARMACEUTICAL SUPPLY CHAIN, AND MAKES THIS INFORMATION AVAILABLE TO RX-360 MEMBERS AND THE PUBLIC VIA RX-360'S WEBSITE. 2648082 0 0 0 1 0 0 0 0 0 1 0 0 1 1 1 0 0 0 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 1 0 0 1 10 0 1 20 1 0 0 0 0 0 0 0 0 X 16 16 0 0 0 0 1 1 1 1 1 0 0 1 1 1 1 0 1 1 0 0 X JIM FRIES 8882181164 1617 JFK BLVD SUITE 546 PHILADELPHIA PA 19103 KATHLEEN SILVA TREASURER 3.00 X X 0 0 0 ROB WELSH CHAIR EMERITUS 3.00 X X 0 0 0 SCOTT KAMMER CHAIR 3.00 X X 0 0 0 JENNIFER STONE VICE CHAIR 3.00 X X 0 0 0 CHRISTIAN LIEBL SECRETARY 2.00 X X 0 0 0 TOM LUPO DIRECTOR 2.00 X 0 0 0 REBECCA ALCANTARA DIRECTOR 2.00 X 0 0 0 ANTHONY DAMAS UNTIL 624 DIRECTOR 2.00 X 0 0 0 CHRIS TRENT START 724 DIRECTOR 2.00 X 0 0 0 CHRISTY MOCNY DIRECTOR 2.00 X 0 0 0 JENNIFER GOODMAN UNTIL 624 DIRECTOR 2.00 X 0 0 0 ROB SMITH DIRECTOR 2.00 X 0 0 0 BILL CAMPAGNA DIRECTOR 2.00 X 0 0 0 ELISE TREUVEY UNTIL 624 DIRECTOR 2.00 X 0 0 0 VARSHA ODIYANDA START 724 DIRECTOR 2.00 X 0 0 0 AMBER HOLLNER DIRECTOR 2.00 X 0 0 0 JOHANNES GROSS DIRECTOR 2.00 X 0 0 0 LIAM KEARY DIRECTOR 2.00 X 0 0 0 TONY ZOOK DIRECTOR 2.00 X 0 0 0 JAMES FRIES CEO 40.00 X 319223 0 2487 BENJAMIN MILLS SENIOR DIRECTOR OF OPERATIONS 40.00 X 151689 0 27830 KENDALL FESHUK MANAGER, MEMBER MANAGEMENT 40.00 X 136440 0 15232 GORDON CURTIS SENIOR DIRECTOR OF FINANCE 40.00 X 109309 0 5921 716661 0 51470 4 0 1 0 MUHLENHAUPT COMPANY LLC 4149 STATION STREET PHILADELPHIA PA 19127 MARKETING SERVICES 150303 JACOBS MANAGEMENT GROUP 1420 WALNUT STREET PHILADELPHIA PA 19102 MANAGEMENT SERVICES 107140 2 LICENSED FEES 900099 2658200 2658200 MEMBERSHIP DUES 900099 1577091 1577091 SPONSORED AUDIT FEES 900099 366476 366476 LICENSED ADMINISTRATIV 900099 294300 294300 4896067 73741 73741 CREDIT CARD REWARDS 900099 1849 1849 1849 4971657 4896067 0 75590 X 321710 1572665 14223 71599 149479 76626 18731 1049685 266931 55027 93534 77520 141698 44801 27823 101908 CREDIT LOSS 54756 DUES AND SUBSCRIPTIONS 28615 BANK CHARGES 23120 4190451 951013 2007043 1518760 1724397 861283 991276 157377 196794 246835 76650 69171 170185 103208 735850 3660812 5825545 37858 908696 1012968 1003650 95668 715340 1146494 2627686 X 2514318 3197859 2514318 3197859 3660812 5825545 X 781206 -97665 0 X 0 0 0 1 1 0 46181 18265 27916 200654 58385 142269 170185 SECURITY DEPOSIT 9013 RIGHT-OF-USE ASSET FOR OFFICE SPACE 712507 DUE FROM RELATED PARTY 14330 735850 OPERATING LEASE OBLIGATION FOR OFFICE SPACE 715340 715340 X PART X, LINE 2: THE INCOME TAX POSITIONS TAKEN BY RX-360 FOR ANY YEAR OPEN UNDER THE VARIOUS STATUTES OF LIMITATIONS ARE THAT RX-360 CONTINUES TO BE EXEMPT FROM INCOME TAXES AND THAT THEY HAVE PROPERLY REPORTED UNRELATED BUSINESS INCOME THAT IS SUBJECT TO INCOME TAXES. RX-360 BELIEVES THAT THERE ARE NO TAX POSITIONS TAKEN OR EXPECTED TO BE TAKEN THAT WOULD SIGNIFICANTLY INCREASE UNRECOGNIZED TAX LIABILITIES WITHIN 12 MONTHS OF THE REPORTING DATE. NONE OF RX-360'S FEDERAL OR STATE INCOME TAX RETURNS ARE CURRENTLY UNDER EXAMINATION. EAST ASIA AND THE PACIFIC - AUSTRALIA, BRUNEI, BURMA, CAMBODIA, 0 0 PROGRAM SERVICES - AUDITS QUALITY AUDITS OF PHARMACEUTICAL SUPPLIES 136340 EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM 0 0 PROGRAM SERVICES - AUDITS QUALITY AUDITS OF PHARMACEUTICAL SUPPLIES 337639 NORTH AMERICA - CANADA AND MEXICO, BUT NOT THE UNITED STATES 0 0 PROGRAM SERVICES - AUDITS QUALITY AUDITS OF PHARMACEUTICAL SUPPLIES 16100 0 0 0 0 0 0 490079 0 490079 0 0 0 0 0 0 PART I, LINE 3: ACCRUAL METHOD IS USED TO ACCOUNT FOR EXPENDITURES. 1 X X X 0 0 0 JAMES FRIES CEO 248523 0 70700 0 0 0 2487 0 0 0 321710 0 0 0 BENJAMIN MILLS SENIOR DIRECTOR OF OPERATIONS 138689 0 13000 0 0 0 6345 0 21485 0 179519 0 0 0 KENDALL FESHUK MANAGER, MEMBER MANAGEMENT 81315 0 55125 0 0 0 9759 0 5473 0 151672 0 0 0 PART I, LINE 3 COMPENSATION FOR THE CEO IS EVALUATED ON AN ANNUAL BASIS BY THE COMPENSATION COMMITTEE AND THE CHAIR OF THE BOARD OF DIRECTORS. COMPENSATION IS BASED ON THE LEVEL OF SKILL REQUIRED FOR THE POSITION, AN EVALUATION OF THE INDIVIDUAL'S ACHIEVEMENT, AND A COMPARISON OF COMPENSATION TO SIMILAR POSITIONS IN THE NON-PROFIT INDUSTRY. THE DETERMINATION OF THE COMPENSATION IS DOCUMENTED BY A COMPENSATION AGREEMENT EXECUTED BY THE CHAIR OF THE BOARD OF DIRECTORS, THE CHAIR OF THE COMPENSATION COMMITTEE, AND THE CEO. FORM 990, PART VI, SECTION A, LINE 6 ANY LEGAL ENTITY MAY BECOME A MEMBER OF RX-360 IF THE FOLLOWING CRITERIA IS MET: 1 - ITS ACTIVITIES RELATE TO THE RESEARCH, DEVELOPMENT, OR MANUFACTURE OF PHARMACEUTICAL OR BIOTECHNOLOGY PRODUCTS, INCLUDING RESEARCH-BASED PHARMACEUTICAL COMPANIES, GENERIC PHARMACEUTICAL COMPANIES, BIOTECHNOLOGY COMPANIES, AS WELL AS SUPPLIERS OF INGREDIENTS AND COMPONENTS OF PHARMACEUTICAL OR BIOTECHNOLOGY PRODUCTS AND SUPPLIERS OF SERVICES RELATING TO THE QUALITY OR SAFETY OF THE PHARMACEUTICAL OR BIOTECHNOLOGY SUPPLY (PROVIDERS OF AUDITING AND CONSULTING SERVICES ARE NOT ELIGIBLE FOR RX-360 MEMBERSHIP); 2 - IT AGREES TO PAY ANNUAL DUES AND ASSESSMENTS THAT ARE SET BY THE BOARD OF DIRECTORS; 3 - IF IT IS A GOVERNMENTAL UNIT OR QUASI-GOVERNMENTAL UNIT OR AN EDUCATIONAL INSTITUTION, IT DOES NOT INVOLVE THE LEGISLATIVE,JUDICIAL, OR EXECUTIVE BRANCHES OF GOVERNMENT, AND ALL STEPS WILL BE TAKEN BY THE ENTITY TO RESIST OR RESTRICT ANY ATTEMPT MADE BY THE LEGISLATIVE, JUDICIAL OR EXECUTIVE BRANCHES TO OBTAIN ACCESS TO RX-360 REPORTS OR CONFIDENTIAL INFORMATION, AND APPROPRIATE MECHANISMS ARE IN PLACE AT THE ENTITY TO ENSURE CONFIDENTIALITY AND TO PREVENT IMPROPER DISCLOSURE. THERE ARE THREE CLASSES OF RX-360 MEMBERS: ONE CLASS FOR MANUFACTURERS OF PHARMACEUTICAL OR BIOTECHNOLOGY FINISHED PRODUCTS WITH $500 MILLION (US DOLLARS) OR MORE IN WORLDWIDE GROSS REVENUE FROM SALES OF PHARMACEUTICAL OR BIOTECHNOLOGY FINISHED PRODUCTS AMONG AFFILIATED ENTITIES; ONE CLASS FOR MANUFACTURERS OF PHARMACEUTICAL OR BIOTECHNOLOGY FINISHED PRODUCTS WITH LESS THAN $500 MILLION (US DOLLARS) IN WORLDWIDE GROSS REVENUE FROM SALES OF PHARMACEUTICAL OR BIOTECHNOLOGY FINISHED PRODUCTS AMONG AFFILIATED ENTITIES AND CONTRACT MANUFACTURERS OF FINISHED DOSAGE FROM PHARMACEUTICAL AND BIOTCHNOLOGY PRODUCTS; AND, ONE CLASS FOR SUPPLIERS OF INGREDIENTS AND COMPONENTS OF SUCH PRODUCTS AND SUPPLIERS OF SERVICES. FORM 990, PART VI, SECTION A, LINE 7A ALL MEMBERS HAVE EQUAL VOTING RIGHTS IN ELECTIONS OF OFFICERS AND ALL MEMBERS ARE ELIGIBLE TO VOTE IN ELECTIONS OF THE BOARD OF DIRECTORS; HOWEVER, VOTING FOR BOARD MEMBERS IS DONE BY CATEGORY OF MEMBERSHIP. THE BYLAWS STATE THAT APPROXIMATELY 65% OF THE MEMBERSHIP OF THE BOARD SHALL BE COMPRISED OF REPRESENTATIVES OF LARGE FINISHED PRODUCT MANUFACTURERS, APPROXIMATELY 10% 0F THE MEMBERSHIP OF THE BOARD SHALL BE COMPRISED OF REPRESENTATIVES OF SMALL OR CONTRACT FINISHED PRODUCT MANUFACTURERS, AND APPROXIMATELY 25% SHALL BE COMPRISED OF REPRESENTATIVES OF SUPPLIERS. FORM 990, PART VI, SECTION A, LINE 7B THE BYLAWS OF RX-360 STATE THAT THE MEMBERS OF RX-360 HAVE THE POWER TO OVERRIDE ANY AMENDMENTS TO THE BYLAWS ADOPTED BY THE BOARD OF DIRECTORS. FORM 990, PART VI, SECTION B, LINE 11B THE CEO FIRST REVIEWS THE 990. ONCE THE CEO IS SATISFIED THAT THE INFORMATION IS ACCURATE AND COMPLETE, IT IS FORWARDED TO THE CHAIR, VICE-CHAIR AND TREASURER FOR THEIR REVIEW. ONCE THEY ARE SATISFIED THAT THE INFORMATION IS ACCURATE AND COMPLETE, THE 990 IS FORWARDED TO THE FULL BOARD FOR REVIEW PRIOR TO SUBMISSION. FORM 990, PART VI, SECTION B, LINE 12C IT IS REVIEWED YEARLY UPON BYLAW REVIEW AND INSTALLATION OF ANNUAL BOARD (JANUARY). FORM 990, PART VI, SECTION B, LINE 15A COMPENSATION FOR THE CEO IS EVALUATED ON AN ANNUAL BASIS BY THE COMPENSATION COMMITTEE AND THE CHAIR OF THE BOARD OF DIRECTORS. COMPENSATION IS BASED ON THE LEVEL OF SKILL REQUIRED FOR THE POSITION, AN EVALUATION OF THE INDIVIDUAL'S ACHIEVEMENT, AND A COMPARISON OF COMPENSATION TO SIMILAR POSITIONS IN THE NON-PROFIT INDUSTRY. THE DETERMINATION OF THE COMPENSATION IS DOCUMENTED BY A COMPENSATION AGREEMENT EXECUTED BY THE CHAIR OF THE BOARD OF DIRECTORS, THE CHAIR OF THE COMPENSATION COMMITTEE, AND THE CEO. FORM 990, PART VI, SECTION C, LINE 19 RX-360'S BYLAWS AND ANTI-TRUST POLICY ARE AVAILABLE ON RX-360'S WEBSITE. ALL OTHER FINANCIAL DOCUMENTS THAT ARE REQUIRED TO BE MADE AVAILABLE TO THE PUBLIC WILL BE AVAILABLE UPON REQUEST. FORM 990, PART IX, LINE 11G PROGRAM QUALITY AUDITORS 797,065. PROFESSIONAL FEES 252,620. FORM 990, PART XI, LINE 8 DURING THE CURRENT FISCAL YEAR, THE ORGANIZATION RECORDED AUDIT ADJUSTMENTS IDENTIFIED DURING THE AUDIT OF THE PRIOR YEAR'S FINANCIAL STATEMENTS. THESE ADJUSTMENTS RELATED TO THE CORRECTION OF PREVIOUSLY MISSTATED BALANCES THAT WERE IDENTIFIED SUBSEQUENT TO THE FILING OF THE PRIOR FORM 990. THE ADJUSTMENTS WERE RECORDED AS PRIOR PERIOD ADJUSTMENTS IN THE ORGANIZATION'S CURRENT-YEAR FINANCIAL STATEMENTS IN ACCORDANCE WITH U.S. GENERALLY ACCEPTED ACCOUNTING PRINCIPLES. AS A RESULT, THE BEGINNING NET ASSET BALANCE IN THE CURRENT-YEAR FORM 990 WAS RESTATED TO REFLECT THESE CORRECTIONS. THE ADJUSTMENTS DID NOT IMPACT THE ORGANIZATION'S CURRENT-YEAR ACTIVITIES OR OPERATIONS. RX-360 EDUCATION AND RESEARCH FOUNDATION PO BOX 40931 PHILADELPHIA PA 19107 845068425 EDUCATION AND RESEARCH PA 501(C)(3) LINE 7 NO 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0